Literature DB >> 25217891

Clinical significance of microcytosis in patients with primary myelofibrosis.

Paolo Strati1, Naveen Pemmaraju1, Zeev Estrov1, Marylou Cardenas-Turanzas1, Sherry Pierce1, Kate J Newberry1, Naval Daver1, Jorge Cortes1, Hagop Kantarjian1, Srdan Verstovsek2.   

Abstract

Microcytosis is a relatively frequent finding in primary myelofibrosis (PMF); however its prognostic significance is unknown. We identified factors associated with microcytosis in PMF and measured its impact on outcomes. Among 725 patients with PMF, 140 (19%) showed microcytosis. In multivariate analysis, factors associated with microcytosis were absence of prior therapy, low iron, low transferrin saturation (satTF), and splenomegaly. Among 375 untreated patients, low satTF and splenomegaly were associated with microcytosis. Overall, microcytosis was associated with a higher risk of transformation to leukemia (p=0.03), but not shorter leukemia-free survival. Microcytosis in PMF may be related to dysregulation of iron homeostasis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Iron homeostasis; Leukemia; Microcytosis; Primary myelofibrosis; Transferrin saturation

Mesh:

Year:  2014        PMID: 25217891      PMCID: PMC4182146          DOI: 10.1016/j.leukres.2014.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  26 in total

1.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

2.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

3.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

4.  Assessment of bone marrow and splenic erythropoiesis in myelofibrosis.

Authors:  A Ferrant; J Rodhain; F Cauwe; M Cogneau; C Beckers; J L Michaux; R Verwilghen; G Sokal
Journal:  Scand J Haematol       Date:  1982-11

5.  Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.

Authors:  Ruben A Mesa; Alan Shields; Thomas Hare; Susan Erickson-Viitanen; William Sun; Nicholas J Sarlis; Victor Sandor; Richard S Levy; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-05-17       Impact factor: 3.156

Review 6.  Primary myelofibrosis: update on definition, pathogenesis, and treatment.

Authors:  Omar I Abdel-Wahab; Ross L Levine
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

7.  Balanced globin synthesis in idiopathic myelofibrosis.

Authors:  S K Ballas; S H Krasnow
Journal:  Clin Chim Acta       Date:  1981-03-05       Impact factor: 3.786

8.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

9.  A low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic disease.

Authors:  Tohru Fujiwara; Takashi Ikeda; Yuki Nagasaka; Yoko Okitsu; Yuna Katsuoka; Noriko Fukuhara; Yasushi Onishi; Kenichi Ishizawa; Ryo Ichinohasama; Naohisa Tomosugi; Hideo Harigae
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia.

Authors:  Pinar Tarkun; Ozgur Mehtap; Elif B Atesoğlu; Ayfer Geduk; Mahmut M Musul; Abdullah Hacihanefioglu
Journal:  Eur J Haematol       Date:  2013-06-28       Impact factor: 3.674

View more
  1 in total

1.  Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

Authors:  Malte Asshoff; Verena Petzer; Matthew R Warr; David Haschka; Piotr Tymoszuk; Egon Demetz; Markus Seifert; Wilfried Posch; Manfred Nairz; Pat Maciejewski; Peter Fowles; Christopher J Burns; Gregg Smith; Kay-Uwe Wagner; Guenter Weiss; J Andrew Whitney; Igor Theurl
Journal:  Blood       Date:  2017-02-10       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.